Pradaxa

ESC 2022 preview – who’s got the XI factor?
ESC 2022 preview – who’s got the XI factor?
EP Vantage
ESC 2022
Bristol Myers Squibb
JNJ
Bayer
Eliquis
Xarelto
bloodthinners
Lixiana
Pradaxa
Flag link:
Reversal Agent for Pradaxa, Praxbind, Now Available Nationwide
Reversal Agent for Pradaxa, Praxbind, Now Available Nationwide
CP Wire
Boehringer Ingelheim
Pradaxa
Praxbind
Flag link:
Reversal Agent for Pradaxa, Praxbind, Now Available Nationwide
Boehringer Ingelheim
Pradaxa
Praxbind
Flag link:
Pradaxa’s 'Red Fish' go to the aquarium in new Boehringer campaign
Pradaxa’s 'Red Fish' go to the aquarium in new Boehringer campaign
Fierce Pharma
Boehringer Ingelheim
Pradaxa
drug ads
television ads
bloodthinners
Flag link:
Many at risk for stroke don’t get anti-clotting drugs
Many at risk for stroke don’t get anti-clotting drugs
Reuters
stroke
atrial fibrillation
Pradaxa
Xarelto
Eliquis
bloodthinners
Flag link:
BI tapping real-world data for Pradaxa
BI tapping real-world data for Pradaxa
BioPharma Dive
Boehringer Ingelheim
Pradaxa
non-valvular atrial fibrillation
Flag link:
Boehringer seeks real-world data to support reversal agent
Boehringer seeks real-world data to support reversal agent
BioPharma Dive
Boehringer Ingelheim
Praxbind
Pradaxa
anticoagulants
anticoagulant reversal
Flag link:
ACC 2016: Boehringer's Pradaxa 'antidote' passes real-world test
ACC 2016: Boehringer's Pradaxa 'antidote' passes real-world test
BioPharma Dive
Boehringer Ingelheim
Pradaxa
Praxbind
Flag link:
BMS expects fast-growing Eliquis to take the lead over Xarelto, Pradaxa
BMS expects fast-growing Eliquis to take the lead over Xarelto, Pradaxa
Fierce Pharma Marketing
bloodthinners
Bristol-Myers Squibb
Eliquis
Xarelto
Pradaxa
Bayer
Pfizer
JNJ
Boehringer Ingelheim
Flag link:
Boehringer wins FDA approval for its Pradaxa antidote with eyes on a bigger market share
Boehringer wins FDA approval for its Pradaxa antidote with eyes on a bigger market share
Fierce Biotech
Boehringer Ingelheim
FDA
Pradaxa
bloodthinners
Praxbind
Flag link:
FDA's review of BI's Pradaxa was 'lax' and 'permissive,' watchdog claims
FDA's review of BI's Pradaxa was 'lax' and 'permissive,' watchdog claims
Fierce Pharma
FDA
Boehringer Ingelheim
Pradaxa
Flag link:
How can Pradaxa, Xarelto and Eliquis finally unseat warfarin? Safety data, analyst says
How can Pradaxa, Xarelto and Eliquis finally unseat warfarin? Safety data, analyst says
Fierce Pharma
Pradaxa
Xarelto
Eliquis
bloodthinners
Warfarin
drug safety
JNJ
Boehringer Ingelheim
Pfizer
Bristol-Myers Squibb
Flag link:
Boehringer says Pradaxa blood-thinning effect shown to be reversible
Boehringer says Pradaxa blood-thinning effect shown to be reversible
Yahoo/Reuters
Boehringer Ingelheim
Pradaxa
stroke
blood thinners
Flag link:
FDA gives Boehringer's Pradaxa antidote a boost with fast-track review
FDA gives Boehringer's Pradaxa antidote a boost with fast-track review
Fierce Pharma
FDA
Boehringer Ingelheim
fast track
Pradaxa
idarucizumab
Flag link:
Pradaxa antidote goes to FDA
Pradaxa antidote goes to FDA
Medical Marketing and Media
Pradaxa
FDA
idaricizumab
Boehringer Ingelheim
Flag link:
Pradaxa antidote enters Phase III
Pradaxa antidote enters Phase III
Medical Marketing and Media
Pradaxa
Boehringer Ingelheim
Flag link:
A tale of two studies: Prescribe Pradaxa 'with caution'? Or rely on FDA's safety backing?
A tale of two studies: Prescribe Pradaxa 'with caution'? Or rely on FDA's safety backing?
Fierce Pharma Marketing
Pradaxa
Boehringer Ingelheim
FDA
Flag link:
Did Boehringer Ingelheim Withhold Pradaxa Data From Regulators?
Did Boehringer Ingelheim Withhold Pradaxa Data From Regulators?
WSJ Online
Pradaxa
Boehringer Ingelheim
Flag link:
NICE backs thousands more scripts for clot-fighters Pradaxa, Xarelto, and Eliquis
NICE backs thousands more scripts for clot-fighters Pradaxa, Xarelto, and Eliquis
Fierce Pharma
NICE
Pradaxa
Xarelto
bloodthinners
Eliquis
Bayer
JNJ
Pfizer
Bristol-Myers Squibb
Boehringer Ingelheim
Flag link:
Boehringer to settle lawsuits against blockbuster drug for $650 mln
Boehringer to settle lawsuits against blockbuster drug for $650 mln
Yahoo/Reuters
Boehringer Ingelheim
Pradaxa
Flag link:

Pages